CR8 hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406333

CAS#: 1786438-30-9 (HCl)

Description: CR8 is a potent and selective inhibitor of CDK. CR8 is a more potent pyridyl analogue of roscovitine. In comparison to roscovirtine, the compound gains in potency toward CK1, which is involved in amyloid-β formation. The R-CR8 enantiomer is slightly more potent than S. CR8 is around 30 times more potent at cellular assay then roscovitine.

Chemical Structure

CR8 hydrochloride
CAS# 1786438-30-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 406333
Name: CR8 hydrochloride
CAS#: 1786438-30-9 (HCl)
Chemical Formula: C24H32Cl3N7O
Exact Mass: 431.24336
Molecular Weight: 540.918
Elemental Analysis: C, 53.29; H, 5.96; Cl, 19.66; N, 18.13; O, 2.96

Price and Availability

Size Price Availability Quantity
100.0mg USD 750.0 Same day
200.0mg USD 1250.0 Same day
500.0mg USD 1950.0 Same day
1.0g USD 2950.0 2 Weeks
2.0g USD 5250.0 2 Weeks
Bulk inquiry

Related CAS #: 1786438-30-9 (HCl)   294646-77-8 (free base)    

Synonym: (R)-CR8; (R)-CR-8; (R)-CR 8; CR8; CR-8; CR 8; CR8 CDK inhibitor; CR8 CDK inhibitor HCl; CR8 CDK inhibitor hydrochloride; (R)-CR8 trihydrochloride;

IUPAC/Chemical Name: (R)-2-((9-isopropyl-6-((4-(pyridin-2-yl)benzyl)amino)-9H-purin-2-yl)amino)butan-1-ol trihydrochloride


InChi Code: InChI=1S/C24H29N7O.3ClH/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20;;;/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30);3*1H/t19-;;;/m1.../s1

SMILES Code: CC[C@@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO.[H]Cl.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly.

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 540.918 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D, Sperling AS, Fink EC, Gasser JA, Wang LR, Corsello SM, Sellar RS, Jan M, Gillingham D, Scholl C, Fröhling S, Golub TR, Fischer ES, Thomä NH, Ebert BL. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 Jun 3. doi: 10.1038/s41586-020-2374-x. Epub ahead of print. PMID: 32494016.

2: Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin- dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. doi: 10.1038/onc.2008.191. Epub 2008 Jun 23. PMID: 18574471.

3: Kabadi SV, Stoica BA, Hanscom M, Loane DJ, Kharebava G, Murray Ii MG, Cabatbat RM, Faden AI. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. Neurotherapeutics. 2012 Apr;9(2):405-21. doi: 10.1007/s13311-011-0095-4. PMID: 22167461; PMCID: PMC3324621.

4: Sallam H, El-Serafi I, Meijer L, Hassan M. Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. BMC Pharmacol Toxicol. 2013 Sep 30;14:50. doi: 10.1186/2050-6511-14-50. PMID: 24079553; PMCID: PMC3849647.

5: Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, Bénard J, Oumata N, Galons H, Meijer L. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer. 2010 Apr;1(4):369-80. doi: 10.1177/1947601910369817. PMID: 21779453; PMCID: PMC3092200.

6: Goulding SP, de Guglielmo G, Carrette LLG, George O, Contet C. Systemic Administration of the Cyclin-Dependent Kinase Inhibitor (S)-CR8 Selectively Reduces Escalated Ethanol Intake in Dependent Rats. Alcohol Clin Exp Res. 2019 Oct;43(10):2079-2089. doi: 10.1111/acer.14177. Epub 2019 Aug 30. PMID: 31403700; PMCID: PMC6779498.

7: Beadling C, Cereseto A, Fan W, Naramura M, Smith KA. Cytokine response gene 8 (CR8) regulates the cell cycle G1-S phase transition and promotes cellular survival. Oncogene. 2001 Mar 29;20(14):1771-83. doi: 10.1038/sj.onc.1204212. PMID: 11313924.

8: Troadec S, Blairvacq M, Oumata N, Galons H, Meijer L, Berthou C. Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. J Biomed Sci. 2015 Jul 17;22(1):57. doi: 10.1186/s12929-015-0163-x. PMID: 26184865; PMCID: PMC4504225.

9: Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, Meijer L. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513. Epub 2013 Dec 9. PMID: 24317512; PMCID: PMC4087096.

10: Kabadi SV, Stoica BA, Loane DJ, Luo T, Faden AI. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13. doi: 10.1038/jcbfm.2013.228. Epub 2014 Jan 8. PMID: 24398934; PMCID: PMC3948132.

11: Billot K, Coquil C, Villiers B, Josselin-Foll B, Desban N, Delehouzé C, Oumata N, Le Meur Y, Boletta A, Weimbs T, Grosch M, Witzgall R, Saunier S, Fischer E, Pontoglio M, Fautrel A, Mrug M, Wallace D, Tran PV, Trudel M, Bukanov N, Ibraghimov-Beskrovnaya O, Meijer L. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F57-F73. doi: 10.1152/ajprenal.00489.2017. Epub 2018 Mar 14. PMID: 29537311; PMCID: PMC6087785.

12: Cosimo E, McCaig AM, Carter-Brzezinski LJ, Wheadon H, Leach MT, Le Ster K, Berthou C, Durieu E, Oumata N, Galons H, Meijer L, Michie AM. Inhibition of NF- κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. Clin Cancer Res. 2013 May 1;19(9):2393-405. doi: 10.1158/1078-0432.CCR-12-2170. Epub 2013 Mar 26. PMID: 23532892.

13: Liu YY, Wang GP, Peng Z, Guo JY, Wu Q, Xie J, Gong SS. E2F1-CDK1 pathway activation in kanamycin-induced spiral ganglion cell apoptosis and the protective effect of CR8. Neurosci Lett. 2016 Mar 23;617:247-53. doi: 10.1016/j.neulet.2016.02.034. Epub 2016 Feb 22. PMID: 26905670.

14: Toribio AL, Pickard D, Cerdeño-Tárraga AM, Petty NK, Thomson N, Salmond G, Dougan G. Complete Genome Sequences of Two Citrobacter rodentium Bacteriophages, CR8 and CR44b. Genome Announc. 2014 May 29;2(3):e00146-14. doi: 10.1128/genomeA.00146-14. PMID: 24874665; PMCID: PMC4038870.

15: Huang BY, Huang HB, Zhang ZJ, Liu ZG, Luo J, Liu M, Luo T. Cell cycle activation contributes to isoflurane-induced neurotoxicity in the developing brain and the protective effect of CR8. CNS Neurosci Ther. 2019 May;25(5):612-620. doi: 10.1111/cns.13090. Epub 2019 Jan 24. PMID: 30676695; PMCID: PMC6488878.

16: Bukanov NO, Moreno SE, Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012 Nov 1;11(21):4040-6. doi: 10.4161/cc.22375. Epub 2012 Oct 3. PMID: 23032260; PMCID: PMC3507499.

17: Kobayashi Y, Watanabe T, Inoue Y, Arakawa H, Mochizuki H, Tokuyama K, Morikawa A. CR8-194--A case of fulminated fatal disseminated Varicella Zoster virus infection with severe pulmonary damage. Paediatr Respir Rev. 2006;7 Suppl 1:S328. doi: 10.1016/j.prrv.2006.04.148. PMID: 17036409.

18: Baker ML, Lancaster T, Chiesa A, Amoretti G, Baker PJ, Barker C, Blundell SJ, Carretta S, Collison D, Güdel HU, Guidi T, McInnes EJ, Möller JS, Mutka H, Ollivier J, Pratt FL, Santini P, Tuna F, Tregenna-Piggott PL, Vitorica-Yrezabal IJ, Timco GA, Winpenny RE. Studies of a Large Odd-Numbered Odd-Electron Metal Ring: Inelastic Neutron Scattering and Muon Spin Relaxation Spectroscopy of Cr8 Mn. Chemistry. 2016 Jan 26;22(5):1779-88. doi: 10.1002/chem.201503431. Epub 2016 Jan 8. PMID: 26748964; PMCID: PMC4744977.

19: Vaknin D, Garlea VO, Demmel F, Mamontov E, Nojiri H, Martin C, Chiorescu I, Qiu Y, Kögerler P, Fielden J, Engelhardt L, Rainey C, Luban M. Level crossings and zero-field splitting in the {Cr8}-cubane spin cluster studied using inelastic neutron scattering and magnetization. J Phys Condens Matter. 2010 Nov 24;22(46):466001. doi: 10.1088/0953-8984/22/46/466001. Epub 2010 Oct 29. PMID: 21403379.

20: Waldmann O, Guidi T, Carretta S, Mondelli C, Dearden AL. Elementary excitations in the cyclic molecular nanomagnet Cr8. Phys Rev Lett. 2003 Dec 5;91(23):237202. doi: 10.1103/PhysRevLett.91.237202. Epub 2003 Dec 4. PMID: 14683210.

Additional Information